Recent data from Phesi, a clinical development analytics company, reveals a significant shift in medical research priorities. Type 2 diabetes has emerged as one of the top five most studied diseases globally in the first half of 2024, surpassing COVID-19. Breast cancer, solid tumors, stroke, and prostate cancer are the top five.
This change coincides with a surge in investment in GLP-1 therapies, such as Ozempic and WeGovy, to address the rising prevalence of obesity. Over 40% of US adults and more than one-quarter of UK adults are now classified as obese.
Phesi’s report highlights another concerning trend: increased clinical trial attrition rates. Approximately 32% of Phase II trials were terminated in the first half of 2024, a significant 56% rise compared to pre-pandemic levels.
This data was gathered from an analysis of 66,935 clinical trials utilizing Phesi’s Trial Accelerator™ platform, incorporating data from over 120 million patients in numerous cohorts.
Source link: https://www.phesi.com/
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
